litlas
Log inCreate account

Keith D. Wilner

Active 1990–2025

66
Papers
29,085
Citations
51
h-index
64
i10-index

Citations

Citations per year for Keith D. Wilner1990: 1 citations1991: 4 citations1992: 5 citations1993: 4 citations1994: 4 citations1995: 3 citations1996: 3 citations1997: 2 citations1998: 8 citations1999: 7 citations2000: 13 citations2001: 8 citations2002: 13 citations2003: 14 citations2004: 10 citations2005: 16 citations2006: 10 citations2007: 13 citations2008: 17 citations2009: 12 citations2010: 31 citations2011: 187 citations2012: 382 citations2013: 431 citations2014: 463 citations2015: 570 citations2016: 505 citations2017: 442 citations2018: 432 citations2019: 1,063 citations2020: 1,000 citations2021: 805 citations2022: 678 citations2023: 457 citations2024: 675 citations2025: 268 citations2026: 8 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,413 citing papers, 28.3% of this breakdownChina: 867 citing papers, 10.2% of this breakdownItaly: 468 citing papers, 5.5% of this breakdownUnited Kingdom: 407 citing papers, 4.8% of this breakdownGermany: 391 citing papers, 4.6% of this breakdownFrance: 389 citing papers, 4.6% of this breakdownJapan: 367 citing papers, 4.3% of this breakdownSpain: 321 citing papers, 3.8% of this breakdownCanada: 273 citing papers, 3.2% of this breakdownSouth Korea: 263 citing papers, 3.1% of this breakdownNetherlands: 231 citing papers, 2.7% of this breakdownSwitzerland: 229 citing papers, 2.7% of this breakdown
0%28.3%Other 22.2%

Institutions

Fields

  • Medicine76%
  • Biochemistry, Genetics and Molecular Biology18.5%
  • Pharmacology, Toxicology and Pharmaceutics1%
  • Computer Science0.8%
  • Mathematics0.7%
  • Immunology and Microbiology0.6%
  • Other2.4%

Topics

  • Lung Cancer Treatments and Mutations16.4%
  • Lung Cancer Research Studies8.2%
  • Cancer Genomics and Diagnostics5.9%
  • Lung Cancer Diagnosis and Treatment4.8%
  • Cancer Immunotherapy and Biomarkers2.6%
  • Cancer therapeutics and mechanisms2.3%
  • Other59.8%

Coauthors

All papers

Open in search
  1. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

    Authors: Benjamin Solomon, Tony Mok, Dong‐Wan Kim, Yi‐Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari, Shrividya Iyer, Arlene Reisman, Keith D. Wilner, Jennifer Tursi, Fiona Blackhall - New England Journal of Medicine 2014 cited by 3,213

  2. Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

    Authors: Alice T. Shaw, Sai‐Hong Ignatius Ou, Yung‐Jue Bang, D. Ross Camidge, Benjamin Solomon, Ravi Salgia, Gregory J. Riely, Marileila Varella‐Garcia, Geoffrey I. Shapiro, Daniel B. Costa, Robert C. Doebele, Long P. Le, Zongli Zheng, Weiwei Tan, Patricia Stephenson, S. Martin Shreeve, L. Tye, James G. Christensen, Keith D. Wilner, Jeffrey W. Clark, A. John Iafrate - New England Journal of Medicine 2014 cited by 1,993

  3. Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer

    Authors: Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinò, Myung‐Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin Solomon, Fiona Blackhall, Yi‐Long Wu, Michael Thomas, Kenneth J. O’Byrne, Denis Moro‐Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne - New England Journal of Medicine 2013 cited by 3,406

  4. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

    Authors: A. Shaw, G.J. Riely, Yung‐Jue Bang, Donghyeon Kim, D.R. Camidge, Benjamin Solomon, Marileila Varella‐Garcia, A. John Iafrate, Geoffrey I. Shapiro, Tiziana Usari, Stewart C. Wang, Keith D. Wilner, Jeffrey W. Clark, S.‐H.I. Ou - Annals of Oncology 2019 cited by 577

  5. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer

    Authors: Gregory J. Riely, Egbert F. Smit, Myung‐Ju Ahn, Enriqueta Felip, Suresh S. Ramalingam, Anne S. Tsao, Melissa L. Johnson, Francesco Gelsomino, Raymond M. Esper, Ernest Nadal, Michael Offin, Mariano Provencio, Jeffrey Clarke, Maen Hussain, Gregory A. Otterson, Ibiayi Dagogo‐Jack, Jonathan W. Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul Wissel, Keith D. Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E. Johnson - Journal of Clinical Oncology 2023 cited by 114

  6. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

    Authors: Alexander Drilon, Jeffrey W. Clark, Jared Weiss, Sai‐Hong Ignatius Ou, D. Ross Camidge, Benjamin Solomon, Gregory A. Otterson, Liza C. Villaruz, Gregory J. Riely, Rebecca S. Heist, Mark M. Awad, Geoffrey I. Shapiro, Miyako Satouchi, Toyoaki Hida, Hidetoshi Hayashi, Danielle Murphy, Sherry Wang, Sherry Li, Tiziana Usari, Keith D. Wilner, Paul K. Paik - Nature Medicine 2020 cited by 393

  7. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

    Authors: Kristin Bergethon, Alice T. Shaw, Sai‐Hong Ignatius Ou, Ryohei Katayama, Christine M. Lovly, Nerina T. McDonald, Pierre P. Massion, Christina T. Siwak-Tapp, Adriana González, Rong Fang, Eugene J. Mark, Julie M. Batten, Haiquan Chen, Keith D. Wilner, Eunice L. Kwak, Jeffrey W. Clark, David P. Carbone, Hongbin Ji, Jeffrey A. Engelman, Mari Mino–Kenudson, William Pao, A. John Iafrate - Journal of Clinical Oncology 2012 cited by 1,557

  8. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Authors: Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon, Robert G. Maki, Sai‐Hong Ignatius Ou, Bruce J. Dezube, Pasi A. Jänne, Daniel B. Costa, Marileila Varella‐Garcia, Woo Ho Kim, Thomas J. Lynch, Panos Fidias, Hannah Stubbs, Jeffrey A. Engelman, Lecia V. Sequist, Weiwei Tan, Leena Gandhi, Mari Mino–Kenudson, Greg C. G. Wei, S. Martin Shreeve, Mark J. Ratain, Jeffrey Settleman, James G. Christensen, Daniel A. Haber, Keith D. Wilner, Ravi Salgia, Geoffrey I. Shapiro, Jeffrey W. Clark, A. John Iafrate - New England Journal of Medicine 2010 cited by 4,504

  9. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

    Authors: Richard S. Finn, Katalin Boér, Igor Bondarenko, Ravindranath Patel, Tamás Pintér, Marcus Schmidt, Yaroslav Shparyk, Anu Thummala, Nataliia Voitko, Eustratios Bananis, Lynn McRoy, Keith D. Wilner, Xin Huang, Sindy Kim, Dennis J. Slamon, Johannes Ettl - Breast Cancer Research and Treatment 2020 cited by 170

  10. Crizotinib in Patients With MET-Amplified NSCLC

    Authors: D. Ross Camidge, Gregory A. Otterson, Jeffrey W. Clark, Sai‐Hong Ignatius Ou, Jared Weiss, Steven Ades, Geoffrey I. Shapiro, Mark A. Socinski, Danielle Murphy, Umberto Conte, Yiyun Tang, Sherry Wang, Keith D. Wilner, Liza C. Villaruz - Journal of Thoracic Oncology 2021 cited by 168

  11. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer

    Authors: Benjamin Solomon, Dong‐Wan Kim, Yi‐Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari, Yiyun Tang, Keith D. Wilner, Fiona Blackhall, Tony Mok - Journal of Clinical Oncology 2018 cited by 412

  12. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer

    Authors: Yi‐Long Wu, James Chih‐Hsin Yang, Dong‐Wan Kim, Shun Lü, Jianying Zhou, Takashi Seto, Jin-Ji Yang, Noboru Yamamoto, Myung‐Ju Ahn, Toshiaki Takahashi, Takeharu Yamanaka, Kemner Allison, Debasish Roychowdhury, Jolanda Paolini, Tiziana Usari, Keith D. Wilner, Kōichi Goto - Journal of Clinical Oncology 2018 cited by 324

  13. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

    Authors: Tony Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Alka Chawla, Rafael Rosell, J. Corral, Maria Rita Migliorino, Adam Płużański, Kay Noonan, Yiyun Tang, M. Pastel, Keith D. Wilner, Yi‐Long Wu - Drugs 2020 cited by 121

  14. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study

    Authors: Yaël P. Mossé, Stephan D. Voss, Megan S. Lim, Delphine Rolland, Charles G. Minard, Elizabeth Fox, Peter C. Adamson, Keith D. Wilner, Susan M. Blaney, Brenda J. Weigel - Journal of Clinical Oncology 2017 cited by 403

  15. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

    Authors: Yaël P. Mossé, Megan S. Lim, Stephan D. Voss, Keith D. Wilner, Katherine Ruffner, Julie Laliberté, Delphine Rolland, Frank M. Balis, John M. Maris, Brenda J. Weigel, Ashish M. Ingle, Charlotte H. Ahern, Peter C. Adamson, Susan M. Blaney - The Lancet Oncology 2013 cited by 701

  16. Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1

    Authors: Mark M. Awad, Ryohei Katayama, Michele McTigue, Wei Liu, Ya-Li Deng, Alexei Brooun, Luc Friboulet, Donghui Huang, Matthew D. Falk, Sergei Timofeevski, Keith D. Wilner, Elizabeth L. Lockerman, Tahsin Khan, Sidra Mahmood, Justin F. Gainor, Subba R. Digumarthy, James R. Stone, Mari Mino–Kenudson, James G. Christensen, A. John Iafrate, Jeffrey A. Engelman, Alice T. Shaw - New England Journal of Medicine 2013 cited by 413

  17. CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib

    Authors: Daniel B. Costa, Susumu Kobayashi, Shuchi S. Pandya, Wee-Lee Yeo, Zhongzhou Shen, Weiwei Tan, Keith D. Wilner - Journal of Clinical Oncology 2011 cited by 590

  18. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

    Authors: D. Ross Camidge, Yung‐Jue Bang, Eunice L. Kwak, A. John Iafrate, Marileila Varella‐Garcia, Stephen B. Fox, Gregory J. Riely, Benjamin Solomon, Sai‐Hong Ignatius Ou, Dong‐Wan Kim, Ravi Salgia, P. Fidias, Jeffrey A. Engelman, Leena Gandhi, Pasi A. Jänne, Daniel B. Costa, Geoffrey I. Shapiro, Patricia LoRusso, Katherine Ruffner, Patricia Stephenson, Yiyun Tang, Keith D. Wilner, Jeffrey W. Clark, Alice T. Shaw - The Lancet Oncology 2012 cited by 1,277

  19. Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor

    Authors: James E. Butrynski, David R. D’Adamo, Jason L. Hornick, Paola Dal Cin, Cristina R. Antonescu, Suresh C. Jhanwar, Marc Ladanyi, Marzia Capelletti, Scott J. Rodig, Nikhil H. Ramaiya, Eunice L. Kwak, Jeffrey W. Clark, Keith D. Wilner, James G. Christensen, Pasi A. Jänne, Robert G. Maki, George D. Demetri, Geoffrey I. Shapiro - New England Journal of Medicine 2010 cited by 867

  20. A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

    Authors: Takaaki Sasaki, Jussi Koivunen, Atsuko Ogino, Masahiko Yanagita, Sarah Nikiforow, Wei Zheng, Christopher S. Lathan, Judith Marcoux, Jinyan Du, Katsuhiro Okuda, Marzia Capelletti, Takeshi Shimamura, Dalia Ercan, Magda Stumpfova, Yun Xiao, Stanislawa Weremowicz, Mohit Butaney, Stéphanie Héon, Keith D. Wilner, James G. Christensen, Michel J. Eck, Kwok‐Kin Wong, Neal I. Lindeman, Nathanael S. Gray, Scott J. Rodig, Pasi A. Jänne - Cancer Research 2011 cited by 601

  21. Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non–Small-Cell Lung Cancer: Results From PROFILE 1014

    Authors: Benjamin Solomon, Federico Cappuzzo, Enriqueta Felip, Fiona Blackhall, Daniel B. Costa, Dong‐Wan Kim, Kazuhiko Nakagawa, Yi‐Long Wu, Tarek Mekhail, Jolanda Paolini, Jennifer Tursi, Tiziana Usari, Keith D. Wilner, Paulina Selaru, Tony Mok - Journal of Clinical Oncology 2016 cited by 271

  22. Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)

    Authors: Jennifer H. Foster, Stephan D. Voss, David Hall, Charles G. Minard, Frank M. Balis, Keith D. Wilner, Stacey L. Berg, Elizabeth Fox, Peter C. Adamson, Susan M. Blaney, Brenda J. Weigel, Yaël P. Mossé - Clinical Cancer Research 2021 cited by 115

  23. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group

    Authors: Allison Magnuson, Suanna S. Bruinooge, Harpreet Singh, Keith D. Wilner, Shadia I. Jalal, Stuart M. Lichtman, Paul G. Kluetz, Gary H. Lyman, Heidi D. Klepin, Mark E. Fleury, Brad Hirsch, Allen S. Melemed, Fernanda I. Arnaldez, Upal Roy, Caroline Schenkel, Shimere Sherwood, Elizabeth Garrett‐Mayer - Clinical Cancer Research 2021 cited by 88

  24. MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib

    Authors: Jochen K. Lennerz, Eunice L. Kwak, A. B. Ackerman, Michael Michael, Stephen B. Fox, Kristin Bergethon, Gregory Y. Lauwers, James G. Christensen, Keith D. Wilner, Daniel A. Haber, Ravi Salgia, Yung‐Jue Bang, Jeffrey W. Clark, Benjamin Solomon, A. John Iafrate - Journal of Clinical Oncology 2011 cited by 430